$IDXG On The Run Again and this time it will be sustained
Updated
Let's recap 
IDXG CC:
1. New York State and AETNA approvals of ThyraMIR®, microRNA assay
2. Talked about the Debt being restructured
3. No more offerings
4. Reduced operating costs
5. Talks of doing business with their BarreGen model
6. Talks of partnering with another bio he didn't discuss.
7. EPS value of $3.25 vs -($12.04) same quarter last year
8. Sales of $3.122 million.
9. Goldman, Rodman and Renshaw, Barclays were on the CC too big boys will be here soon enough count on it.
10. 64% of the S/S is SHORT
11. Raised $14 million in gross equity and restructured over $9.3 million of secured debt
12. Revenue increased 39%
Also most importantly the Patent Approval!!!
IDXG European Patent Decision data.epo.org/publication-server/pdf-document?pn=2772550&ki=B1&cc=EP
ALSO FULL YEAR HIGHLIGHTS READ HERE: ih.advfn.com/p.php?pid=nmona&article=74215692
IDXG CC: 1. New York State and AETNA approvals of ThyraMIR®, microRNA assay
2. Talked about the Debt being restructured
3. No more offerings
4. Reduced operating costs
5. Talks of doing business with their BarreGen model
6. Talks of partnering with another bio he didn't discuss.
7. EPS value of $3.25 vs -($12.04) same quarter last year
8. Sales of $3.122 million.
9. Goldman, Rodman and Renshaw, Barclays were on the CC too big boys will be here soon enough count on it.
10. 64% of the S/S is SHORT
11. Raised $14 million in gross equity and restructured over $9.3 million of secured debt
12. Revenue increased 39%
Also most importantly the Patent Approval!!!
IDXG European Patent Decision data.epo.org/publication-server/pdf-document?pn=2772550&ki=B1&cc=EP ALSO FULL YEAR HIGHLIGHTS READ HERE: ih.advfn.com/p.php?pid=nmona&article=74215692
Comment
Alerted this on Twitter earlier in the day. Will post charts in real time next time.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.